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Chronic recurrent multifocal osteomyelitis
(CRMO) – advancing the diagnosis
M. R. Roderick1,2* , R. Shah2, V. Rogers2, A. Finn1,3 and A. V. Ramanan2
Abstract
Background: Chronic recurrent multifocal osteomyelitis (CRMO) is a little known inflammatory bone disease
occurring primarily in children and adolescents. Delays in referral and diagnosis may lead to prolonged courses of
antibiotics with in-patient care, unnecessary radiation exposure from multiple plain radiographs or bone scans and
repeated surgery including bone biopsies.
Children (aged < 18 years) diagnosed with CRMO between January 2005 and December 2012, reviewed at Bristol
Royal Hospital for Children were included and all available data collected. Information regarding CRMO was sent to
all orthopaedic surgeons in the region in 2009.
The aim of the study was to examine the features of the cohort, to examine the length of time to diagnosis and to
explore the criteria used for diagnosis with and without biopsy.
Findings: Over an 8 year period, 41 patients were diagnosed with CRMO. Symptom onset occurred at a median of
9 years of age and time to diagnosis had a median of 15 months (range 0–92). Correlation coefficient analysis for
time to diagnosis by year showed statistical significance with a decreasing trend. From the cohort data, diagnostic
criteria were developed; applied retrospectively, 34 (83 %) children may have been diagnosed using the criteria,
without a biopsy.
Conclusions: The data suggest that increasing knowledge of this condition may shorten time to diagnosis. Use of
the Bristol diagnostic criteria by an experienced clinician may obviate the need for biopsy in some patients.
Keywords: Chronic recurrent non-bacterial osteomyelitis (CRMO), Pamidronate, Autoinflammatory, Cohort, Chronic
recurrent multifocal osteomyelitis (CNO)
Abbreviations: CNO, Chronic nonbacterial osteomyelitis; CRMO, Chronic recurrent multifocal osteomyelitis; CRP, C-
reactive protein; ESR, Erythrocyte sedimentation rate; MRI, Magnetic resonance image; NSAID, Non-steroidal anti-
inflammatory drug; WB-MRI, Whole body magnetic resonance image
Background
Chronic recurrent multifocal osteomyelitis (CRMO), also
known as chronic nonbacterial osteomyelitis (CNO), is
an inflammatory bone disease occurring primarily in
children and adolescents unfamiliar to many. It was first
described in 1972 by Giedion as “an unusual form of
multifocal bone lesions with subacute and chronic sym-
metrical osteomyelitis” [1].
There are now around 400 cases of CRMO described
in the literature predominantly as case series. The true
prevalence is difficult to assess as it is a little-known dis-
ease and likely to be vastly underdiagnosed [2].
The consistent feature of CRMO is the insidious on-
set of pain with swelling and tenderness localised over
the affected bones. Involvement of the clavicle is the
classical picture; however, the metaphyses and epiphy-
ses of the femur, tibia or humerus are also frequently
affected. Lesions may occur in any bone, including
vertebrae [3, 4].
CRMO has recently been classified as an autoinflam-
matory disorder (rather than autoimmune). These in-
flammatory conditions are characterised by episodes of
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systemic inflammation including serological signs of
inflammation (CRP, ESR, IL-6, TNF-α) occurring in
the absence of autoantibodies, pathogens or antigen-
specific T cells [5, 6].
As the condition is obscure to many doctors, and
commonly being misdiagnosed as bacterial osteomyelitis,
delays in referral and correct diagnosis may lead to pro-
longed courses of antibiotics (often given intravenously
in hospital), unnecessary radiation exposure from mul-
tiple plain radiographs or bone scans and repeated bone
biopsies before a diagnosis is made.
The diagnosis of CRMO is made by exclusion of
other diseases, and commonly requires a bone biopsy
in order to exclude infection, neoplasia or langerhans’
cell histiocytosis.
Findings
The Bristol Royal Hospital for Children provides a local
and a tertiary referral service for specialist paediatric
rheumatology care for families across the South West of
England and nationally.
Children (aged less than 18 years) who had been
previously diagnosed with CRMO between January
2005 and December 2012, reviewed at Bristol Royal
Hospital for Children were included in the review.
These diagnoses had been made following a variety of
presentations, using clinical, radiological and some-
times histological findings.
In 2009, the Bristol rheumatology and immunology
department wrote to all the orthopaedic surgeons in the
South West of England. This manuscript aimed to raise
awareness of CRMO as a condition and recommended
referral to the Bristol service.
We retrospectively reviewed clinical, biological and
radiological data on children diagnosed with CRMO
during the specified period. Complete medical history
including age at first symptoms, age at diagnosis, sex,
constitutional symptoms at disease onset, number of
painful sites involved, family history, past history and
treatment history were recorded from the clinical notes.
The notes were available for review on all 41 patients, all
37 magnetic resonance images (MRI) scan reports were
reviewed but only 36/41 (88 %) plain radiograph results
were available.
Inflammatory markers and bone biopsy results were
recorded and imaging reports of plain radiography, bone
scans and whole body – magnetic resonance imaging
(WB-MRI) were collected.
A descriptive analysis of patient characteristics was
performed obtaining data from peripheral hospitals
where necessary. Data was entered into a table and was
examined by two independent researchers. The length
of time (in months) from the onset of symptoms to
diagnosis for each child was plotted on a scatter chart
and the correlation coefficient was calculated with p
values using MS Excel.
Forty one patients (31 female and 10 male) were diag-
nosed as CRMO and assessed at the Bristol centre over
an 8 year period to December 2012. The ethnicity was
not recorded in the notes; patients were referred from
the South West of England and Wales.
The median age at the onset of first symptom was
9 years (range 1–13) and the median age at diagnosis
was 11 years (range 1–17). The median time from onset
of symptoms to diagnosis was 15 months (range 1–92).
Bony pain with or without swelling was the most com-
mon presenting complaint. Patients were most com-
monly initially referred to an orthopaedic surgeon (21
patients, 51 %), or a general paediatrician (10 patients,
24 %). One patient was referred to a general surgeon be-
fore being referred to the Bristol centre.
Before the diagnosis of CRMO was made, the most
common differential diagnoses were infective osteomye-
litis, malignancy e.g. Ewing’s sarcoma, Langerhans’ cell
histiocytosis, non-specific musculoskeletal disorders, ju-
venile idiopathic arthritis and viral infections.
The initial clinical presentation was in a single site
in 22 patients (54 %) but after each patient had been
fully evaluated by different methods (clinical examin-
ation, plain x-ray, MRI or bone scan) only 10 patients
(24 %) had single site involvement (6 of which were
clavicle alone).
The most common bones involved at presentation (by
clinical assessment only) were tibia (27 patients, 66 %)
and clavicle (14 patients, 34 %); spinal symptoms were
present in six patients (15 %). Only five (12 %) patients
had symmetrical symptoms on presentation. Constitu-
tional symptoms (e.g. fever, malaise), skin lesions (pus-
tules or psoriasis) and joint swelling were observed in 6
(15 %), 4 (10 %) and 7 (17 %) patients respectively. No
associated clinically apparent inflammatory bowel dis-
ease was seen in our cohort.
In all patients complete blood count, renal function
and liver function tests were normal. A C-reactive pro-
tein (CRP) level was available in 28 patients (median
value 7 mg/l, range 1–30 mg/l) and mildly raised in 14
(>10 g/L). Erythrocyte sedimentation rate (ESR) was
measured in 19 patients (median value 27 mm/h, range
1–72) in 16 of whom it was raised (≥11 mm/h).
The length of time (in months) from the onset of
symptoms to diagnosis for each child was plotted on a
scatter chart showing the trend line for all children re-
ferred (Fig. 1). The correlation coefficient R = −0.29 (P =
0.03 using a directional test) showed a statistically sig-
nificant decreasing trend for time to diagnosis. Bone bi-
opsy had been performed in a total of 32 patients
(78 %), 29 of these were biopsied before being referred
to our centre; 20 of these patients had one biopsy, 11
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patients had undergone biopsy on 2 occasions and 1
patient had a biopsy on three occasions before the diag-
nosis was made.
In 24 patients the pathology report described inflam-
mation on biopsy specimens while seven patients had no
obvious inflammatory changes. One patient’s biopsy was
reported as showing features consistent with a chon-
droma (however, subsequently, WB-MRI showed mul-
tiple typical CRMO lesions). Plasma cell infiltrates were
seen in 16 patients (50 %). Reactive bone changes, pre-
dominantly fibrosis, were seen in 23 out of 32 patients
(72 %); only two of these had no evidence of inflamma-
tion. All specimens were sent for culture and all but one
were negative. One biopsy specimen grew S. aureus on
enrichment culture but there were no histological fea-
tures of infection or inflammation; an MRI showed sym-
metrical lesions and repeat biopsy and culture (off
antibiotics) was negative.
Twelve children were referred without biopsy of
whom nine did not require a biopsy for diagnosis. Five
of these had typical multiple lesions on MRI scan, one
had a single affected area and had a sibling with typ-
ical CRMO, and three patients had a solitary lesion of
the clavicle.
Plain radiograph of the major symptomatic site was
available in 36 out of 41 patients. It was abnormal in
28/36 (78 %) revealing lytic lesions in 18 (50 %), areas
of sclerotic bone in 19 (53 %) and periosteal reaction
in 12 patients (33 %). Among the eight patients with
normal plain radiographs, the median length of symp-
toms was 3.5 months compared with 8.5 months in the
abnormal group (not significant, p >0.05 by Mann–
Whitney U test). Whole body MRI detected an abnor-
mal lesion at the symptomatic site in seven of these
eight patients with normal x-ray. Fourteen patients
had had a bone scan prior to being seen by the
rheumatology team. In three patients (3/14) the bone
scan identified an asymptomatic site.
Whole body MRI has been described as being helpful
in reaching the diagnosis [7, 8]. Out of the 41 patients,
37 (90 %) patients were evaluated with MRI, 30 with
whole body MRI and 7 with localised imaging. In total
162 lesions were detected (see Table 1). Of the 162 le-
sions identified by imaging, 47 (29 %) were asymptom-
atic and detected only by MRI. Unifocal involvement was
observed in the clavicle (6 patients), mandible (1 patient),
tibia (1 patient) and femur (1 patient). 32 spinal lesions
were detected in 13 patients, 6 of these had only one
spinal lesion with other lesions elsewhere. Two patients
Table 1 Distribution of different lesions by imaging
Site affected Number of detected
lesion
% of total lesions n =
162
Pelvis 14 9
Femur 16 10
Tibia 40 25
Fibula 8 5
Small bone in
foot
16 10
Humerus 7 4
Radius 5 3
Ulna 4 2
Mandible 1 1
Clavicle 12 7
Ribs 6 3
Sternum 1 1
Vertebra 32 20
- Cervical (2) (1)
- Thoracic (18) (11)
- Lumbar (3) (2)
- Sacral (8) (5)
- Coccyx (1) (1)
Total 162 100
Fig. 1 Correlation plots between interval between onset of symptoms and year of diagnosis for all 41 patients. R = −0.29
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only had spinal involvement but both of these had more
than one lesion, and neither was evaluated by whole
body MRI (therefore silent lesions may have been
present but undetected).
Twenty two patients (54 %) received at least one
course of intravenous antibiotics before the diagnosis
was made. Fourteen (34 %) patients did not require ther-
apy other than non-steroidal anti-inflammatory drugs
(NSAIDs). Three patients were treated with corticoste-
roids but none of them reported associated improve-
ment. Six patients (with pain resistant to treatment with
NSAIDs) were treated with methotrexate; two patients
made no response, four patients went into remission but
two of them relapsed on follow up. One patient was
treated with sulfasalazine and responded well, remaining
clinically asymptomatic after 4 years on treatment; how-
ever, repeat MRI showed four new lesions in this patient.
Where there was no response to NSAIDs, and other
agents (where given), pamidronate (as intravenous cycles
of 1 mg/kg/day for 3 consecutive days) was used to seek
to control disease activity. By the end of 2012, twenty-
two children (54 %) had had some treatment with pami-
dronate. Thirteen had completed at least one year of
treatment with 11 children having MRI both before and
after treatment; the two children without MRI scans
were treated before 2010 and after treatment both re-
ported a good response and were discharged from
follow-up. Seven children had started pamidronate
therapy but had not yet completed treatment at the
time of writing. Two patients had started treatment but
had given up after nine months as their symptoms were
not improving. Of these two children (who did not
complete treatment), one had improved on follow-up
and the other was commenced on biological therapy
with etanercept in 2012. These findings are published
in more detail elsewhere [9].
Of the thirteen patients who had completed one year
of pamidronate at analysis, nine (69 %) patients had sub-
stantial relief from pain (no longer requiring any anal-
gesia) after starting pamidronate therapy, and four had
ongoing significant pain. Two of these (with ongoing
pain) had new lesions identified on MRI and the other
two had persistent disease activity on MRI albeit im-
proved from their initial scans.
As expected with bisphosphonate therapy, flu-like
symptoms with fever and myalgia were very common
particularly during the first cycle although, with prior
warning, all patients tolerated therapy very well. No
major side effects were observed.
Conclusions
Our findings suggest that raising the awareness of
CRMO may lead to earlier diagnosis. The protracted
interval of 15 months (median) between symptom onset
and diagnosis is well recognised and is partially ex-
plained by the lack of specific clinical, laboratory and
imaging findings, and the difficulty in distinguishing the
inflammation from infection. In spite of being described
in 1972 [1], CRMO is still not well recognised and is
likely to be substantially more common than is currently
diagnosed. Delay in diagnosis can lead to prolonged ad-
missions for intravenous antibiotics (sometimes multiple
admissions), and multiple biopsies which, it can be ar-
gued, are rarely necessary for the diagnosis of CRMO.
The presence of typical clinical findings (bone pain +/- localised swelling without 
significant local or systemic features of inflammation or infection) 
AND
The presence of typical radiological findings (plain x-ray: showing combination of 
lytic areas, sclerosis and new bone formation or preferably STIR MRI: showing bone 
marrow oedema +/- bone expansion, lytic areas and periosteal reaction)
AND EITHER
Criterion 1: more than one bone (or clavicle alone) without significantly raised CRP 
(CRP < 30 g/L).
OR
Criterion 2: if unifocal disease (other than clavicle), or CRP >30 g/L, with bone biopsy 
showing inflammatory changes (plasma cells, osteoclasts, fibrosis or sclerosis) with no 
bacterial growth whilst not on antibiotic therapy.
Fig. 2 Bristol diagnostic criteria for CRMO
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It is likely that in places where CRMO is seen less
commonly, the diagnosis will be forgotten if publications
or specific awareness-raising methods are not utilised.
Multifocal involvement is common but may be sub-
clinical; distinguishing between CRMO and bacterial
osteomyelitis is made easier when multiple sites are evi-
dent clinically or on imaging. Using WB-MRI scans on
all children with suspected unifocal osteomyelitis is un-
likely to be practical or necessary; however, once CRMO
has been considered WB-MRI along with consideration
of other typical features may make the diagnosis more
obvious, and potentially avoid the need for biopsy.
On the basis of the findings of this cohort, the criteria
in Fig. 2 were formulated by the authors of the paper for
use by the department. Using these criteria retrospect-
ively, thirty-four children could have been diagnosed by
criterion 1, with 6 children requiring a biopsy (criterion
2) for diagnosis, either for a solitary lesion (not clavicle)
or because of atypical features such as very young age
(<2 years). One child did not fit these criteria as she
had only ankle involvement but her symptoms were
mild, her sibling had a diagnosis of CRMO, and symp-
toms responded well to NSAIDs (making other causes
of bone inflammation unlikely). Some patients with
CRMO may have a markedly raised CRP but these are
likely to require a biopsy in order to exclude an infec-
tious agent.
Twelve children were without biopsy at referral of
whom nine did not require a biopsy for diagnosis.
Using these criteria for diagnosis provides a framework
for avoiding biopsy in children with typical disease;
however, these criteria cannot be validated by this
retrospective audit as the clinicians and/or radiologist
may have been aware of a biopsy report when making
the diagnosis. It is very straightforward to declare the
MRI findings as ‘typical’ for CRMO whilst holding a
bone marrow report with suggestive features. The clin-
ical vignette and available imaging would need to be
shown to a blinded audience in order to validate these
criteria objectively.
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